Renaissance Capital logo

Bellevue Life Sciences Acquisition Filed Terms, Nasdaq: BLACU

Blank check company backed by Bellevue Capital Management targeting the biotech sector.

Industry: SPAC

Latest Trade: ()

First Day Return:

Return from IPO:

Industry: SPAC

We are a newly organized blank check company. While we may pursue an acquisition opportunity in any business industry or sector, we intend to capitalize on our management team’s differentiated ability to source, acquire and manage a business in the healthcare industry, more specifically in the biotechnology sector. Our founding management team is led by Kuk Hyoun (Peter) Hwang, the Founding and Managing Partner of Bellevue Capital Management (BCM); David J. Yoo, the Chief Financial Officer of BCM; and Jun Chul Whang, General Counsel and Partner of BCM. Our founding management team has decades of combined experience in healthcare investing and extensive experience in mergers and acquisitions, investment banking, and investment management including within the healthcare sector. We are focused on companies developing the next generation of biologics which include therapeutic antibodies, engineered protein and enzyme drugs, cellular therapies, engineered viruses and bacteria, and DNA- and RNA-modifying technologies, using advanced molecular biology and biochemistry. We will consider companies with pipeline programs in clinical “Proof-of-Concept” studies (often from Phase 1 to 2a) to develop novel medicines to address diseases which cannot yet be cured or sufficiently managed.
more less
IPO News for Bellevue Life Sciences Acquisition
more
IPO Data
IPO File Date 04/29/2022
Offer Price
Price Range $10.00 - $10.00
Offer Shares (mm) 6.0
Deal Size ($mm) $60
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date
Offer Price
Price Range $10.00 - $10.00
Offer Shares (mm) 6.0
Deal Size ($mm) $60
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Bellevue, WA
Founded 2020
Employees 2